BioMarin Pharmaceutical has officially concluded its substantial acquisition of Amicus Therapeutics, a move that promises to significantly expand BioMarin’s footprint…
Read More
AI Tools Revolutionize Pharmaceutical Administration, Freeing Up Valuable Human Capital
The pharmaceutical industry is experiencing a significant transformation as artificial intelligence (AI) tools move beyond experimental phases to deliver tangible…
Read More
Moving Beyond the Binary: How the Convergence of Small and Large Molecules is Reshaping Pharmaceutical R&D
Pharmaceutical R&D is at an inflection point, witnessing a profound transformation that challenges the historical dichotomy between small and large…
Read More
Regeneron cuts White House pricing deal, offers new gene therapy for free – Pharmaceutical Technology
Regeneron Pharmaceuticals has entered into a significant drug pricing agreement with the White House, marking a pivotal moment in the…
Read More
Regulatory round-up: Novartis, Sanofi and Arrowhead secure CHMP blessings – Pharmaceutical Technology
The European Committee for Medicinal Products for Human Use (CHMP) has issued positive opinions on three promising new drug candidates,…
Read More
OZMOSI and Planview Forge Strategic Alliance to Revolutionize Pharmaceutical R&D Planning with AI-Powered Clinical Intelligence
OZMOSI and Planview have announced a significant partnership aimed at transforming how pharmaceutical organizations approach research and development (R&D) planning.…
Read More
Cochrane Review Challenges Clinical Significance of Anti-Amyloid Alzheimer’s Drugs, Pharmaceutical Companies Reaffirm Efficacy
A comprehensive review of 17 clinical trials by the esteemed Cochrane organization has cast doubt on the clinically meaningful benefits…
Read More
Moving beyond the binary: how the convergence of small and large molecules is reshaping pharmaceutical R&D
Pharmaceutical research and development stands at a pivotal juncture, experiencing a profound transformation that challenges long-held dichotomies in drug design.…
Read More
Precision Medicine in Early Oncology Trials: Biomarkers as Strategic Drivers – Pharmaceutical Technology
The landscape of oncology drug development is undergoing a profound transformation, increasingly centered on precision immunotherapies where biomarker-defined patient populations…
Read More
Emerging therapies bring hope for frail HNSCC patients unfit for standard treatment – Pharmaceutical Technology
The global burden of head and neck squamous cell carcinoma (HNSCC) is on an upward trajectory, with an estimated increase…
Read MoreYOU MAY HAVE MISSED
